Skip to content

A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients

A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06021041
Enrollment
900
Registered
2023-09-01
Start date
2018-01-13
Completion date
2024-02-01
Last updated
2023-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Brief summary

This is a retrospective clinical study to analyze the clinical characteristics, complications, and effects of different treatment options on long-term prognosis of severe tuberculosis patients. All cases of severe tuberculosis diagnosed between 2016 and 2021 were included in the electronic medical record system of one center, and data such as demographics, hospitalization information, clinical information, laboratory or imaging examinations, treatment plans, and outcomes were collected.

Interventions

None listed

Sponsors

Tongji Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. For patients with severe pulmonary tuberculosis, imaging and grading diagnosis meet any of the following: 1. Damaged lung ≥ 1 lobe 2. Chest CT shows lesions in ≥3 lung lobes 3. Hematogenous disseminated pulmonary tuberculosis 4. caseous pneumonia 5. bronchial tuberculosis 6. Multiple hilar or mediastinal lymph node enlargement in primary pulmonary tuberculosis 7. Rifampicin-resistant, multidrug-resistant, polydrug-resistant or pan-drug-resistant tuberculosis 8. Combined more than 2 cavities over 8mm 9. Tuberculous massive hemoptysis 10. Pulmonary tuberculosis complicated with acute infection (including multidrug-resistant bacterial infection, fungal infection or multiple infection) 11. Combined with extrapulmonary tuberculosis * Intracranial tuberculosis, spinal cord and/or meningeal tuberculosis * Pleural effusion, pericardial effusion * Empyema or empyema, hemopneumothorax, tracheobronchopleural fistula and severe infection. * Heart failure caused by cardiac tamponade or constrictive pericarditis * Multiple sites of lymphatic tuberculosis or surgery is necessary * Cervical lymphatic tuberculosis * Mediastinal lymphatic tuberculosis * Abdominal or retroperitoneal lymph node tuberculosis * Abdominal tuberculosis, tuberculous peritonitis (ascites or multiple serous cavities) * Intestinal tuberculosis causes complete or incomplete intestinal root obstruction or perforation or massive bleeding or severe abdominal infection * Gastrointestinal hemorrhage caused by tuberculosis of the digestive system, etc. * Musculoskeletal tuberculosis * Spinal (cervical, thoracic, lumbar, sacral) tuberculosis * Bones in other parts * Merge surrounding abscess * Urinary or renal tuberculosis * Renal failure or damaged blood vessels caused by renal tuberculosis * Ureteral stenosis or blockage caused by urinary tuberculosis * Adrenal tuberculosis in hypoadrenal insufficiency * Liver tuberculosis 2. Age and gender are not limited.

Exclusion criteria

* Patients with no clear diagnosis at discharge. * Patients judged by the investigator to be unsuitable for inclusion in this protocol. * The discharge diagnosis was central nervous system tuberculosis, or tuberculous meningitis, or tuberculous cerebrospinal meningitis, or tuberculous meningoencephalitis, or tuberculous encephalitis, or tuberculous brain abscess, or spinal tuberculosis, or tuberculous Hydrocephalus, and is currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frameDescription
2-year survival rate2 years2-year survival rate
2-year disability rate2 years2-year disability rate

Secondary

MeasureTime frameDescription
The number of participants with the presence of clinical symptoms2 years
Incidence of complications in patients with different treatment regimens2 yearsIncidence of complications in patients with different treatment regimens
Length of hospital stay for patients2 yearsLength of hospital stay for patients
Proportion of patients admitted to the ICU2 yearsProportion of patients admitted to the ICU

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026